AU2022254741A1 - Treatment of cancer with kdm4 inhibitors - Google Patents

Treatment of cancer with kdm4 inhibitors Download PDF

Info

Publication number
AU2022254741A1
AU2022254741A1 AU2022254741A AU2022254741A AU2022254741A1 AU 2022254741 A1 AU2022254741 A1 AU 2022254741A1 AU 2022254741 A AU2022254741 A AU 2022254741A AU 2022254741 A AU2022254741 A AU 2022254741A AU 2022254741 A1 AU2022254741 A1 AU 2022254741A1
Authority
AU
Australia
Prior art keywords
cancer
fold
diagnosed
patient
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022254741A
Other languages
English (en)
Inventor
Young K. Chen
Michael Clarke
Frank Perabo
Jeffrey A. Stafford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tachyon Therapeutics Inc
Celgene Corp
Original Assignee
Tachyon Therapeutics Inc
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tachyon Therapeutics Inc, Celgene Corp filed Critical Tachyon Therapeutics Inc
Publication of AU2022254741A1 publication Critical patent/AU2022254741A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2022254741A 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors Pending AU2022254741A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173219P 2021-04-09 2021-04-09
US63/173,219 2021-04-09
US202163252542P 2021-10-05 2021-10-05
US63/252,542 2021-10-05
US202263297960P 2022-01-10 2022-01-10
US63/297,960 2022-01-10
PCT/US2022/024087 WO2022217100A1 (en) 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors

Publications (1)

Publication Number Publication Date
AU2022254741A1 true AU2022254741A1 (en) 2023-11-16

Family

ID=83545127

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022254741A Pending AU2022254741A1 (en) 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors

Country Status (6)

Country Link
US (1) US20250025451A1 (enExample)
EP (1) EP4319748A4 (enExample)
JP (1) JP2024518712A (enExample)
AU (1) AU2022254741A1 (enExample)
CA (1) CA3214399A1 (enExample)
WO (1) WO2022217100A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991090T3 (es) 2017-03-30 2024-12-02 Univ Freiburg Albert Ludwigs Inhibidores de KDM4
JP2025532101A (ja) * 2022-09-21 2025-09-29 セルジーン コーポレーション 3-({[(4r)-7-{メチル[4-(プロパン-2-イル)フェニル]アミノ}-3,4-ジヒドロ-2h-1-ベンゾピラン-4-イル]メチル}アミノ)ピリジン-4-カルボン酸のl-リジン塩、ヒストンデメチラーゼ阻害剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307643D0 (en) * 2003-04-02 2003-05-07 Cyclacel Ltd Markers
BR112015022391B1 (pt) * 2013-03-12 2021-12-21 Abbvie Inc Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos
US20160113911A1 (en) * 2013-06-06 2016-04-28 The General Hospital Corporation Methods and compositions for the treatment of cancer
CN106660982B (zh) * 2014-06-25 2020-09-08 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂
WO2018102736A1 (en) * 2016-12-01 2018-06-07 The General Hospital Corporation Methods for the treatment of cancer
ES2991090T3 (es) * 2017-03-30 2024-12-02 Univ Freiburg Albert Ludwigs Inhibidores de KDM4
WO2018222831A1 (en) * 2017-05-31 2018-12-06 The Children's Medical Center Corporation TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA
WO2019083594A1 (en) * 2017-08-21 2019-05-02 The General Hospital Corporation COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
AU2022331536A1 (en) * 2021-08-18 2024-02-22 Celgene Corporation Process for preparing histone demethylase inhibitors

Also Published As

Publication number Publication date
WO2022217100A1 (en) 2022-10-13
EP4319748A4 (en) 2025-02-26
CA3214399A1 (en) 2022-10-13
EP4319748A1 (en) 2024-02-14
US20250025451A1 (en) 2025-01-23
JP2024518712A (ja) 2024-05-02

Similar Documents

Publication Publication Date Title
Manni et al. JMJD family proteins in cancer and inflammation
JP7323592B2 (ja) 癌を治療するための併用療法
US20220062240A1 (en) Methods of treating cancer using a clk inhibitor
JP2008533053A (ja) ヒストン脱アセチル化酵素阻害剤は、がん細胞を上皮増殖因子受容体阻害剤に対して感受性にする
JP7442439B2 (ja) Kdm4阻害剤
JP7462789B2 (ja) Idh1阻害剤耐性対象の治療方法
US20250025451A1 (en) Treatment of cancer with kdm4 inhibitors
EP4085053A1 (en) Treatment of cancer with cdk12/13 inhibitors
JP2022511498A (ja) Cdk4/6阻害剤に耐性の癌を治療するための方法
WO2012178038A1 (en) Methods of treating cancer
JP2025525935A (ja) 子宮漿液性がんを治療するためのwee1化合物
Soucie et al. Molecular basis of mast cell disease
JP7163495B2 (ja) B細胞リンパ腫の治療のための医薬組成物
CN116209452A (zh) 用于治疗aml的疗法和rara激动剂、低甲基化剂和bcl-2抑制剂的用途
US8598188B2 (en) Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
US20210079384A1 (en) Non-invasive detection of response to a targeted therapy
WO2015134603A2 (en) Methods for treating cancer
WO2019039390A1 (ja) 若年性骨髄単球性白血病治療薬
CN114525342A (zh) Linc02806在肝细胞癌诊断和治疗中的应用
CN114574580A (zh) 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用
US20210260057A1 (en) Compositions and methods targeting glutamine and its metabolism for diagnosing and treating cancer and therapy-associated side effects
WO2007099852A1 (ja) 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
CN116904588B (zh) Linc01633在胃癌诊断和治疗中的应用
JPWO2011078312A1 (ja) 肝細胞癌患者に対する化学療法の治療効果予測方法
US20220184029A1 (en) Compositions and methods for treating neuroblastoma